Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:ARVN NASDAQ:KRTX NASDAQ:MOR NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$30.04-3.4%$29.39$25.17▼$36.45$5.13B0.541.97 million shs4.32 million shsARVNArvinas$9.16-1.6%$8.31$5.90▼$29.61$683.52M2.392.49 million shs3.85 million shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APCRXPacira BioSciences$21.66+0.8%$25.14$16.00▼$27.64$965.60M0.4532,490 shs377,680 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-1.14%-3.54%+12.52%+17.19%+10.64%ARVNArvinas-3.62%-1.59%+23.64%+18.00%-64.96%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%MORMorphoSys0.00%0.00%0.00%0.00%0.00%PCRXPacira BioSciences-2.41%-8.36%-18.78%-1.51%+21.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$30.04-3.4%$29.39$25.17▼$36.45$5.13B0.541.97 million shs4.32 million shsARVNArvinas$9.16-1.6%$8.31$5.90▼$29.61$683.52M2.392.49 million shs3.85 million shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APCRXPacira BioSciences$21.66+0.8%$25.14$16.00▼$27.64$965.60M0.4532,490 shs377,680 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-1.14%-3.54%+12.52%+17.19%+10.64%ARVNArvinas-3.62%-1.59%+23.64%+18.00%-64.96%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%MORMorphoSys0.00%0.00%0.00%0.00%0.00%PCRXPacira BioSciences-2.41%-8.36%-18.78%-1.51%+21.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.93Moderate Buy$42.8542.63% UpsideARVNArvinas 2.43Hold$16.1876.68% UpsideKRTXKaruna Therapeutics 0.00N/AN/AN/AMORMorphoSys 0.00N/AN/AN/APCRXPacira BioSciences 2.43Hold$33.4054.20% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, KRTX, PCRX, ALKS, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/23/2025ALKSAlkermesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$38.00 ➝ $45.0010/22/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $47.0010/22/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral10/15/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$8.00 ➝ $6.0010/15/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$8.00 ➝ $6.0010/14/2025ALKSAlkermesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/7/2025ARVNArvinasPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$16.009/27/2025ALKSAlkermesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.18$2.56 per share11.73$9.05 per share3.32ARVNArvinas$263.40M2.55N/AN/A$8.17 per share1.12KRTXKaruna Therapeutics$654K19,239.07N/AN/A$33.24 per share9.92MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17PCRXPacira BioSciences$700.97M1.39$4.35 per share4.98$16.86 per share1.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0814.4421.931.6823.15%24.86%17.14%10/28/2025 (Estimated)ARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)KRTXKaruna Therapeutics-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/APCRXPacira BioSciences-$99.56M-$2.78N/A8.43N/A-18.08%13.29%6.61%11/5/2025 (Estimated)Latest ARVN, KRTX, PCRX, ALKS, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025PCRXPacira BioSciences$0.66N/AN/AN/A$182.86 millionN/A10/29/2025Q3 2025ARVNArvinas-$0.74N/AN/AN/A$29.36 millionN/A10/28/2025Q3 2025ALKSAlkermes$0.41N/AN/AN/A$355.23 millionN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85ARVNArvinasN/A5.645.64KRTXKaruna TherapeuticsN/A19.3119.31MORMorphoSys4.981.381.38PCRXPacira BioSciences0.502.381.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%ARVNArvinas95.19%KRTXKaruna TherapeuticsN/AMORMorphoSys18.38%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%ARVNArvinas4.73%KRTXKaruna Therapeutics13.20%MORMorphoSys0.05%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableARVNArvinas42073.42 million69.95 millionOptionableKRTXKaruna Therapeutics33938.15 million33.16 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionableARVN, KRTX, PCRX, ALKS, and MOR HeadlinesRecent News About These CompaniesPacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®October 23 at 8:00 AM | globenewswire.comPacira down after FDA filing for generic ExparelOctober 21 at 6:59 PM | msn.comPacira notified of abbreviated New Drug Application filing from WhiteOakOctober 21 at 1:58 PM | msn.comPacira BioSciences stock falls after generic challenge to EXPARELOctober 21 at 1:58 PM | au.investing.comPacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®October 21 at 9:30 AM | markets.businessinsider.comPacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®October 21 at 8:30 AM | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by AnalystsOctober 21 at 5:47 AM | marketbeat.comPacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene TherapyOctober 20 at 4:01 PM | globenewswire.comEasterly Investment Partners LLC Boosts Holdings in Pacira BioSciences, Inc. $PCRXOctober 17, 2025 | marketbeat.comKLP Kapitalforvaltning AS Increases Stake in Pacira BioSciences, Inc. $PCRXOctober 16, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Given "Sell (D)" Rating at Weiss RatingsOctober 10, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Gagnon Securities LLCOctober 8, 2025 | marketbeat.comGagnon Advisors LLC Has $5.10 Million Position in Pacira BioSciences, Inc. $PCRXOctober 8, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Has $1.29 Million Holdings in Pacira BioSciences, Inc. $PCRXOctober 8, 2025 | marketbeat.comGreenwood Capital Associates LLC Takes $314,000 Position in Pacira BioSciences, Inc. $PCRXOctober 4, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of "Moderate Buy" by AnalystsSeptember 26, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $11.54 Million Stock Holdings in Pacira BioSciences, Inc. $PCRXSeptember 23, 2025 | marketbeat.comPacira BioSciences (PCRX): Evaluating Valuation After Recent Share Price MomentumSeptember 17, 2025 | finance.yahoo.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Why the Precious Metal Nobody Talks About Could Be Your Best BetBy Jordan Chussler | October 4, 2025Rocket Lab USA Receives Wall Street Validation: Time to Buy?By Ryan Hasson | October 16, 20253 Fintech Stocks That Are Set to Rise as Rates FallBy Gabriel Osorio-Mazilli | October 6, 2025ARVN, KRTX, PCRX, ALKS, and MOR Company DescriptionsAlkermes NASDAQ:ALKS$30.04 -1.05 (-3.38%) Closing price 04:00 PM EasternExtended Trading$30.50 +0.46 (+1.51%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Arvinas NASDAQ:ARVN$9.16 -0.15 (-1.61%) Closing price 04:00 PM EasternExtended Trading$9.21 +0.05 (+0.53%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Karuna Therapeutics NASDAQ:KRTXKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 10/22/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Pacira BioSciences NASDAQ:PCRX$21.66 +0.17 (+0.79%) Closing price 04:00 PM EasternExtended Trading$21.84 +0.18 (+0.81%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
